about
The P2X7 receptor is a key modulator of aerobic glycolysis5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypesPharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cellsThe Ca2+ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 actionExtracellular ATP causes ROCK I-dependent bleb formation in P2X7-transfected HEK293 cellsNucleotide receptors: an emerging family of regulatory molecules in blood cells5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo.Extracellular nucleotide and nucleoside signaling in vascular and blood diseaseNucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors.AMP affects intracellular Ca2+ signaling, migration, cytokine secretion and T cell priming capacity of dendritic cellsNucleotide signalling during inflammationA role for calcium in Bcl-2 action?Stimulation of P2 purinergic receptors induces the release of eosinophil cationic protein and interleukin-8 from human eosinophils.Endoplasmic reticulum, Bcl-2 and Ca2+ handling in apoptosis.Calcium and apoptosis: facts and hypotheses.P2X(7) receptor: Death or life?Modulation of P2X7 receptor functions by polymyxin B: crucial role of the hydrophobic tail of the antibiotic molecule.Purinergic signaling in scarring.Nimodipine inhibits IL-1β release stimulated by amyloid β from microglia.Extracellular purines promote the differentiation of human bone marrow-derived mesenchymal stem cells to the osteogenic and adipogenic lineages.The sixth sense: hematopoietic stem cells detect danger through purinergic signaling.P2X7/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells.Purinergic signaling in atherosclerosis.Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling.Extracellular ATP acting at the P2X7 receptor inhibits secretion of soluble HLA-G from human monocytes.Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease?A role for P2X7 in microglial proliferation.Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth.Shaping immune responses through the activation of dendritic cells' P2 receptors.P2Z purinoreceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death.Extracellular ATP activates transcription factor NF-kappaB through the P2Z purinoreceptor by selectively targeting NF-kappaB p65ATP-mediated cytotoxicity in microglial cells.Role of the purinergic P2Z receptor in spontaneous cell death in J774 macrophage cultures.Macrophages loaded with doxorubicin by ATP-mediated permeabilization: potential carriers for antitumor therapy.P2X(7): a growth-promoting receptor-implications for cancer.Differential regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95- and anticancer drug-induced apoptosis.Increased sensitivity to extracellular ATP of fibroblasts from patients affected by systemic sclerosis.Extracellular adenosine 5'-triphosphate modulates interleukin-6 production by human thyrocytes through functional purinergic P2 receptors.The P2Y14 receptor of airway epithelial cells: coupling to intracellular Ca2+ and IL-8 secretion.Stimulation of purinergic receptors modulates chemokine expression in human keratinocytes.
P50
Q24296731-DEB5B0AA-1AB8-445C-A665-8B07595B4750Q28242799-70200405-C11C-460E-8AE4-CE5538F2714EQ28346734-9AE47E92-0D31-41AD-B1AD-83DDA201C033Q28366131-8A570DAA-7B93-4DE0-82A8-A696E4FBA8F2Q28565083-2F948656-E30B-4196-ADD2-6B1F36930F29Q28678595-9458DB6D-3289-4516-8B3E-E628DBB50470Q33489581-EC090B0B-BE25-49E9-97D2-127A66C73F43Q34047834-AB64AAB8-4246-4AD1-8F96-DAB5FD993EAEQ34140085-3AFC85FE-8E6F-4339-BDE5-159F815A53DAQ34280067-79FFAB41-6258-4B8C-9F0A-08D2112386CCQ34464511-39D31545-8284-4091-B9BF-B7CA93D4925BQ34648872-7C91A3E0-4165-401A-8260-69EE9B5BF086Q34648872-F26B29FA-E153-44EE-88FD-0F6E6FC64E36Q35045133-F8F3B10E-535C-4597-9722-5AEB923C33A5Q35051301-F637FEFD-29FA-4ABB-B191-A47D6B897249Q35591703-3E6B8F28-A257-4539-9566-A8B05A7FBAE3Q35591703-CD41E210-B76B-4474-8732-15EFCD95C5B6Q36173773-FE2033FA-8B9B-4175-9397-A152246940A7Q36357782-536389F1-4285-4822-9D3D-6845A33CFC20Q36385326-8C355B61-2A31-4744-998C-2196DE046761Q36476748-BD8FEFC8-0EB3-4E75-B963-32C2E18FFDC2Q36715918-821C8365-C178-464C-9F29-2F6B8240489DQ38025606-5D3EC5CA-7F51-42E7-8DAE-C0249B5AF122Q38325287-B982CF18-FDD5-47B1-AA25-E62DBD08CE9CQ38338463-EA42F323-1C74-4F0C-BFB4-DAAF1CB9AF58Q39527042-E748F3CB-FEC1-4F64-91B8-6B9D22C159A2Q39800283-3E2E920A-0D81-4856-9BB7-7F5CF3C41DBCQ40065701-F15F0297-81CC-4982-96BF-7459EE60BC41Q40256464-06A5D254-89B6-49F1-B7C6-2758018C5C40Q40420727-6D665DD2-8681-4D96-961E-F660AC5C1C40Q40730253-BCCAEC19-C7CB-44C1-8998-6F5CF886FA21Q40958387-7A05D2DC-9172-46B3-83EB-6A6C24A2DEE3Q41067861-85AC0E8D-2DBC-4212-BF90-56155CA85B8CQ41080063-7C93DBA3-D166-4830-BE63-25DA7B1AE800Q41240335-5E854901-5617-4236-B4F0-4368D240EA66Q41429570-5B8FAA69-9CC6-4F34-97E7-B9340418321FQ42087948-ABFEBE53-1F30-429D-888A-E1447ADBA80BQ42196578-9B105465-957C-4D9E-8B3A-47991E813AC2Q42410241-197E6A8B-2C83-40F5-891E-A14F159ED67AQ42476052-82FC3F44-DFE1-49A0-919B-E53334AB8788
P50
description
hulumtues
@sq
researcher
@en
հետազոտող
@hy
name
Davide Ferrari
@ast
Davide Ferrari
@en
Davide Ferrari
@es
Davide Ferrari
@nl
Davide Ferrari
@sl
type
label
Davide Ferrari
@ast
Davide Ferrari
@en
Davide Ferrari
@es
Davide Ferrari
@nl
Davide Ferrari
@sl
prefLabel
Davide Ferrari
@ast
Davide Ferrari
@en
Davide Ferrari
@es
Davide Ferrari
@nl
Davide Ferrari
@sl
P1053
F-5644-2015
P106
P1153
55613776800
P21
P31
P3829
P496
0000-0002-5727-9204